{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:22:46Z","timestamp":1758763366887,"version":"3.44.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.kint.2018.06.022","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T23:01:28Z","timestamp":1537398088000},"page":"661-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evocalcet in the management of secondary hyperparathyroidism in dialysis patients"],"prefix":"10.1016","volume":"94","author":[{"given":"Patrick S.","family":"Parfrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.06.022_bib1","doi-asserted-by":"crossref","first-page":"e01953161","DOI":"10.1371\/journal.pone.0195316","article-title":"A\u00a0novel calcimimetic agent, evocalcet (MT-4580\/KHK 7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in\u00a0vivo or in\u00a0vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2018.06.022_bib2","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2018.06.022_bib3","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.06.022_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.06.022_bib5","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.kint.2017.12.014","article-title":"Incidence, predictors, and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial","volume":"93","author":"Floege","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.06.022_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818304770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818304770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:50:24Z","timestamp":1758761424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818304770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0085253818304770"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.06.022","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evocalcet in the management of secondary hyperparathyroidism in dialysis patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.05.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}